GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$39.16 USD
+0.26 (0.67%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $39.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.16 USD
+0.26 (0.67%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $39.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth B Momentum A VGM
Zacks News
Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DNL
SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
by Zacks Equity Research
SCYNEXIS' (SCYX) shares soar 134% year to date, owing to partnership with big wig GSK plc for the development of its antifungal tablet, Brexafemme.
Why Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?
by Zacks Equity Research
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment
by Zacks Equity Research
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.
Glaxo (GSK) Down 3.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer's (PFE) RSV Vaccine Abrysvo Gets Approval in EU
by Zacks Equity Research
Pfizer's (PFE) RSV vaccine, Abrysvo, gets approval in Europe to protect infants through maternal immunization as well as for older adults.
Here's Why GSK (GSK) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak
by Zacks Equity Research
Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.
Pfizer's (PFE) RSV Vaccine Gets FDA Nod for Pregnant Women
by Zacks Equity Research
The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for the prevention of lower respiratory tract disease in infants through administration to pregnant women.
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
by Ekta Bagri
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
The Zacks Analyst Blog Highlights Microsoft, Mastercard, ServiceNow, Lowe's and GSK
by Zacks Equity Research
Microsoft, Mastercard, ServiceNow, Lowe's and GSK are included in this Analyst Blog.
Top Research Reports for Microsoft, Mastercard & ServiceNow
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Mastercard Incorporated (MA) and ServiceNow, Inc. (NOW).
Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology
by Zacks Equity Research
Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.
Top Stock Reports for Walt Disney, Boeing & General Electric
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), The Boeing Company (BA) and General Electric Company (GE).
Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Adaptimmune (ADAP) is expected to provide regulatory and developmental updates on its pipeline programs in its upcoming earnings release, given the absence of marketed products in its portfolio.
Stock Market News for Jul 27, 2023
by Zacks Equity Research
U.S. stocks ended mixed on Wednesday, with the S&P 500 and the Nasdaq ending slightly lower, as major indexes made a failed attempt to bounce back after the Fed hiked interest rates yet again.
GSK Beats on Q2 Earnings & Sales, Raises 2023 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across all segments, especially HIV and vaccine. GSK raises guidance for earnings and sales. Shares rise in pre-market trading post the announcement.
Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More
by Zacks Equity Research
Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.
GSK (GSK) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Glaxo (GSK) delivered earnings and revenue surprises of 14.12% and 5.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bristol-Myers (BMY) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results.
GSK or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GSK vs. TECH: Which Stock Is the Better Value Option?
AstraZeneca (AZN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales, partially offset by lower sales of legacy drugs.
GSK Gears Up for Q2 Earnings: Will It Surpass Estimates?
by Zacks Equity Research
We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.
Vir Biotechnology (VIR) Down on Influenza Study Failure
by Zacks Equity Research
Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.
Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.